Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Chronic Dosing (12-weeks), Two-Period, Placebo-Controlled, Crossover, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of Two Doses of L1-79 for the Treatment of the Core Deficits in Social-Communication Interaction in Adolescents and Young Adults With Autism Spectrum Disorder

X
Trial Profile

A Randomized, Double-Blind, Chronic Dosing (12-weeks), Two-Period, Placebo-Controlled, Crossover, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of Two Doses of L1-79 for the Treatment of the Core Deficits in Social-Communication Interaction in Adolescents and Young Adults With Autism Spectrum Disorder

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Racemetirosine (Primary)
  • Indications Pervasive child development disorders
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Yamo Pharmaceuticals
  • Most Recent Events

    • 20 Nov 2023 According to a Yamo Pharmaceuticals, The study is being conducted at eight clinical sites in the United States (US) (Including Columbia University, Cortica, Ohio State, RUSH, SARRC, Thompson Center at CHOC and University of Missouri)
    • 20 Nov 2023 According to a Yamo Pharmaceuticals, LLC media release, company look forward to beginning business development discussions ahead of the data readout next summer
    • 20 Nov 2023 According to a Yamo Pharmaceuticals, LLC media release, With the completion of this Phase 2 study enrollment, company has initiated a Phase 3 readiness program to optimize L1-79 development timeline.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top